PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
April 1, 1999The Thoracic and Cardiovascular Surgeon

Percutaneous Transluminal Septal Ablation in Hypertrophic Obstructive Cardiomyopathy

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does percutaneous transluminal septal myocardial ablation reduce LV outflow-tract gradient in symptomatic patients with hypertrophic obstructive cardiomyopathy?

Population

114 symptomatic patients with hypertrophic obstructive cardiomyopathy, mean age 53.3 +/- 15.6 years, 56…

Design

Case_series

Follow-up

3 months

Authors

HSHubert SeggewißLFLaura M. FaberUGU. Gleichmann

Discussion

Loading...

Member takes

Overview

Supports PTSMA for acute LVOTG reduction in HOCM; leaves open durability, safety, and comparative outcomes.

Structured PICO

Does percutaneous transluminal septal myocardial ablation reduce LV outflow-tract gradient in symptomatic patients with hypertrophic obstructive cardiomyopathy?

P
Population
114 symptomatic patients with hypertrophic obstructive cardiomyopathy (HOCM), mean age 53.3 +/- 15.6 years, 56 female, most in NYHA class III. Includes 5 patients with prior myectomy and 5 with DDD pacer.
I
Intervention
Percutaneous transluminal septal myocardial ablation (PTSMA) by alcohol-induced occlusion of septal branches (injection of absolute alcohol via central lumen after balloon occlusion).
O
Outcome
Reduction of left ventricular outflow-tract gradient (LVOTG) at restsurrogate

Percutaneous transluminal septal myocardial ablation significantly reduces LV outflow-tract gradient and improves symptoms in patients with HOCM, though it carries risks of in-hospital mortality and pacemaker dependency.

Cite This Study

Seggewiß et al. (1999) studied this question.

synapsesocial.com/papers/6a809230cf96de1eb9c884ffhttps://doi.org/10.1055/s-2007-1013118
View Full Paper
Ask AI
Bookmark
Share